Options
Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A nationwide, populationābased cohort study
Journal
International Journal of Rheumatic Diseases
Journal Volume
27
Journal Issue
1
ISSN
1756-1841
1756-185X
Date Issued
2023-12-11
Author(s)
ChiaāChu Meng
DerāYuan Chen
YiāHsing Chen
WenāNan Huang
HsināHua Chen
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>To assess the association between antirheumatic drugs and of the risk of nonalcoholic fatty liver disease (NAFLD) in a nationwide rheumatoid arthritis (RA) cohort.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Using claim data from the 2000ā2020 National Health Insurance Research Database, we identified 21ā457 incident patients with RA from 2002 to 2020 without prior liver diseases. A timeāvarying multivariable Cox regression model was applied to estimate for the association of NAFLD with the use of antirheumatic drugs after adjusting potential confounders, show as adjusted hazard ratios (aHRs) with 95% confidence interval (CIs). Subgroup analyses were conducted based on ageā, sexā, and obesityārelated comorbidities.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Multivariable timeādependent Cox regression analyses showed that defined daily dose (DDD) of NSAID (aHR, 1.03; 95% CI: 1.02ā1.05) and prednisolone equivalent dose >5āmg/day (aHR, 2.39; 95% CI: 1.85ā3.09) were risk factors of NAFLD in patients with RA, while prednisolone equivalent dose ā¤5āmg/day (aHR of 0.53; 95% CI: 0.40ā0.71) and HCQ use (aHR of 0.75; 95% CI: 0.60ā0.93) were associated with a decreased risk of NAFLD. In addition, a history of hospitalizations, number of outpatient visits, age, male, and leflunomide use were associated with the development of NAFLD in some subgroups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study reveals that NSAID use and prednisolone equivalent dose >5āmg/day were associated with an increased risk of NAFLD in patients with RA, while the use of HCQ and prednisolone equivalent dose ā¤5āmg/day decreased the risk of NAFLD.</jats:p></jats:sec>
Publisher
Wiley
Type
journal-article